New study aims to evaluate a novel pediatric TB diagnostic tool and treatment response

SEATRAC member and Department of Global Health principal investigator Dr. Sylvia LaCourse and team have begun a new five-year study titled “CRISPR-TB for pediatric TB diagnosis and treatment response” funded by the National Institutes of Health will support an evaluation of a CRISPR-based technology to target and detect Mycobacterium tuberculosis cell-free DNA (cfDNA). 

The study leverages an existing collaboration between KEMRI CRDR who leads the clinical cohorts, while the Hu Lab will lead the CRISPR-TB platform optimization and testing of samples. The UW GWACh team led by Dr. LaCourse will provide oversight for the study design, execution, and analysis.

Find full announcement from Gloabal WACh: New study aims to evaluate a novel pediatric TB diagnostic tool and treatment response | Global WACh (washington.edu)